Pneumonia caused by Staphylococcus aureus

Current Respiratory Medicine Reviews

Volumn 5, Issue 1, 2009, Pages 62-67

  Haessler, Sarah D ^a,b   Brown, Richard B ^a,b  

^a BAYSTATE MEDICAL CENTER   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Pneumonia; Staphylococcus aureus

Indexed keywords

ANTIBIOTIC AGENT; CEFTOBIPROLE; CEPHALOSPORIN DERIVATIVE; CLINDAMYCIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; LINEZOLID; MACROLIDE; METICILLIN; NAFCILLIN; OXACILLIN; PENICILLIN BINDING PROTEIN 2A; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; TELAVANCIN; TIGECYCLINE; VANCOMYCIN;

AREA UNDER THE CURVE; CLINICAL FEATURE; COMMUNITY ACQUIRED PNEUMONIA; CREATININE BLOOD LEVEL; DRUG PENETRATION; DRUG PROTEIN BINDING; HOSPITAL INFECTION; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIOLOGY; NEPHROTOXICITY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; STAPHYLOCOCCAL PNEUMONIA; STAPHYLOCOCCUS AUREUS; VENTILATOR ASSOCIATED PNEUMONIA;

EID: 65949083139     PISSN: 1573398X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157339809787354056     Document Type: Review

References (66)

1. Mainous A, Hueston W, Everett C, Diaz V. Nasal carriage of Staphylococcus aureus and methicillin-resistant S. aureus in the United States, 2001-2002. Ann Fam Med 2006; 4: 132-7.
2. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious diseases society of American/American thoracic society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44: S27-72.
3. Niederman MS, Mandell LA, Anzueto A, et al. Guidelines for the management of adults with community-acquired pneumonia. diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001; 163: 1730-54.
4. Albaum MN, Hill LC, Murphy M. Interobserver reliability of the chest radiograph in community-acquired pneumonia. Chest 1996; 110: 343-50.
5. klompas m. Does this patient have ventilator-associated pneumonia? JAMA 2007; 297: 1583-93.
6. Fabregas N, Ewig S, Torres A, et al. Clinical diagnosis of ventilator associated pneumonia revisited; comparative validation using immediate post-mortem lung biopsies. Thorax 1999; 54: 867-73.
7. Osler W. The Principals and practice of medicine. 4th ed.New York; D. Appleton & Co. 1901.
8. Chickering H, Park J. Staphylococcus aureus pneumonia. JAMA 1919; 72: 617-26.
9. Morens DM, Taubenberger JK, Fauci AS. Predominant role of bacterial pneumonia as a cause of death in pandemic influenza; implications for pandemic influenza preparedness. J Infect Dis 2008; 198: 962-70.
10. Reimann H. Primary Staphylococcic Pneumonia. JAMA 1933; 101: 514-20.
11. Ede S, Davis G, Holmes F. Staphylococcic Pneumonia. JAMA 1959; 170: 638-43.
12. Harrison TR. Principals of internal medicine. 3rd ed. New York; McGraw-Hill 1958.
13. Bartlett JG, O'Keefe P, Tally FP, Louie TJ, Gorbach SL. Bacteriology of hospital -acquired pneumonia. Arch Intern Med 1986; 146: 868-71.
14. Kollef MK, Shorr A, Tabak YP, et al. Epidemiology and outcomes of health-care associated pneumonia. Chest 2005; 128: 3854-62.
15. Kaye MG, Fox MJ, Bartlett JG, Braman SS, Glassroth J. The clinical spectrum of Staphylococcus aureus pulmonary infection. Chest 1990; 97: 788-92.
16. CDC NNIS System. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004; pp. 470-85.
17. Sader HS, Streit JM, Fritsche TR, Jones RN. Antimicrobial susceptibility of gram-positive bacteria isolated from european medical centres; results of the daptomycin surveillance programme (2002-2004). Clin Microbiol Infect 2006; 12: 844-52.
18. Gonzalez C, Rubio M, Romero-vivas J, Gonzalez M, Picazo JJ. Bacteremic pneumonia due to Staphylococcus aureus; a comparison of disease caused by methicillin-resistant and methicillin-susceptible organisms. Clin Infect Dis 1999; 29: 1171-7.
19. Rello J, Torres A, Ricart M, et al. Ventilator-associated pneumonia by Staphylococcus aureus. Am J Respir Crit Care Med 1994; 150: 1545-49.
20. Rello J, Diaz E, Rodriguez A. Etiology of ventilator-associated pneumonia. Clin Chest Med 2005; 26: 87-95.
21. CDC NNIS System. National Nosocomial Infections Surveillance (NNIS) report, data summary from October 1986-April 1998, Issued June 1998. Am J Infect Control 1998; pp. 522-33.
22. Pujol M, Corbella X, Pena C, et al. Clinical and epidemiological findings in mechanically-ventilated patients with methicillin-resistant Staphylococcus aureus pneumonia. Eur J Clin Microbiol Infect Dis 1998; 17: 622-8.
23. Zahar J-R, Clec'h C, Tafflet M, et al. Is Methicillin resistance associated with a worse prognosis in Staphylococcus aureus ventilator-associated pneumonia? Clin Infect Dis 2005; 41: 1224-31.
24. Combes A, Luyt C-E, Fagon J-Y, et al. Impact of methicillin resistance on outcome of Staphylococcus aureus ventilator-associated pneumonia. Am J Respir Crit Care Med 2004; 170: 789-92.
25. Rubinstein E, Kollef MK, Nathwani D. Pneumonia caused by methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2008; 46: S378-85.
26. Francis JS, Doherty MC, Lopatin UA, et al. Severe community-onset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the panton-valentine leukocidin genes. Clin Infect Dis 2005; 40: 100-7.
27. Gonzales R, Malone DC, Maselli JH, Sande MA. Excessive antibiotic use for acute respiratory infections in the United States. Clin Infect Dis 2001; 33: 757-62.
28. Moran G, Amii R, Abrahamian F, Talan D. Methicillin-resistant Staphylococcus aureus in community-acquired skin infections. Emerg Infect Dis 2005; 11: 928-30.
29. Centers for disease control and prevention. Four pediatric deaths from community-acquired methicillin-resistant Staphylococcus aureus-minnesota and north dakota, 1997-1999. MMWR Morb Mortal Wkly Rep1999; 48: 707-10.
30. Herold BC, Immergluck LC, Marana MC, et al. Community-acquired methicillin-resistant Staphylococcus aureus in children with no identifiable risk. JAMA 1998; 279: 593-8.
31. Hageman JC, Uyeki TM, Francis JS, et al. Severe community-acquired pneumonia due to Staphylococcus aureus, 2003-2004 Influenza Season. Emerg Infect Dis 2006; 12: 894-9.
32. Centers for disease control and prevention. Severe methicillin-resistant Staphylococcus aureus community-acquired pneumonia associated with Influenza - Louisiana and Georgia, December 2006 - January 2007. MMWR Morb Mortal Wkly Rep 2007; 56: 325-9.
33. Adam H, McGeer A, Simor A. Fatal case of post-influenza, community-associated MRSA pneumonia in an Ontario teenager with subsequent familial transmission. Canada Communicable Dis Rep 2007; 33: 45-8.
34. Kollef MK, Micek ST. Methicillin-resistant Staphylococcus aureus; a new community-acquired pathogen? Curr Opin Infect Dis 2006; 19: 161-8.
35. Ma XX, Ito T, Tiensasitorn C, et al. Novel type of Staphylococcal cassette chromosome mec identified in community-acquired methicillin-resistant Staphylococcus aureus strain. Antimicrob Agents Chemother 2002; 46: 1147-52.
36. Deurenberg RH, Vink C, Kalenic S, et al. The molecular evolution of methicillin-resistant Staphylococcus aureus. Clin Microbiol Infect 2007; 13: 222-35.
37. Montgomery CP, Boyle-Vavra S, Adem PV, et al. Comparison of virulence in community-associated methicillin-resistant Staphylococcus aureus pulsotypes usa300 and usa400 in a rat model of pneumonia. J Infect Dis 2008; 198: 561-70.
38. Deresinski S. Methicillin-Resistant Staphylococcus aureus; An evolutionary, epidemiologic, and theraputic odyssey. Clin Infect Dis 2005; 40: 562-73.
39. Lina G, Piemont Y, Godail-Gamot F, et al. Involvement of panton-valentine leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia. Clin Infect Dis 1999; 29: 1128-32.
40. Gillet Y, Issartel B, Vanhems P, et al. Association between Staphylococcus aureus strains carrying gene for Panton-Valentine leukocidin and highly lethal necrotising pneumonia in young immuno-competent patients. Lancet 2002; 359: 753-8.
41. Morgan M. Diagnosis and treatment of Panton-Valentine leukocidin (PVL)-associated staphylococcal pneumonia. Int J Antimicrob Agents 2007; 30: 289-96.
42. Boussaud V, Parrot A, Mayaud C, et al. Life-threatening hemoptysis in adults with community-acquired pneumonia due to Panton-Valentine Leukocidin-secreting Staphylococcus aureus. Intensive Care Med 2003; 29: 1840-3.
43. Gillet Y, Vanhems P, Lina G, et al. Factors predicting mortality in necrotizing community-acquired pneumonia caused by Staphylococcus aureus containing panton-valentine leukocidin. Clin Infect Dis 2007; 45: 315-21.
44. Obed A, Schnitzbauer AA, Bein T, et al. Fatal pneumonia caused by panton-valentine leukocidin-positive methicillin-resistant Staphylococcus aureus (PVL-MRSA) transmitted from a healthy donor in living-donor liver transplantation. Transplantation 2006; 81: 121-4.
45. LeBlanc L, Pepin J, Toulouse K, et al. Fluoroquinolones and risk for methicillin-resistant Staphylococcus aureus, Canada. Emerg Infect Dis 2006; 12: 1398-405.
46. Charbonneau P, Parienti J-J, Thibon P, et al. Fluoroquinolone use and methicillin-resistant Staphylococcus aureus isolation rates in hospitalized patients; a quasi experimental study. Clin Infect Dis 2006; 42: 778-84.
47. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171: 388-416.
48. Chastre J, Wolff M, Fagon J-Y, et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults. JAMA 2003; 290: 2588-98.
49. Paradisi F, Giampaolo C, Messeri D. Antistaphylococcal (MSSA, MRSA, MSSE, MRSE) antibiotics. Med Clin North Am 2001; 85: 1-17.
50. Van der Auwera P, Klastersky J, Thys JP, Meunier-Carpenter F, Legrand JC. Double-blind, placebo-controlled study of oxicillin combined with rifampin in the treatment of Staphylococcal infections. Antimicrob Agents Chemother 1985; 28: 467-72.
51. Rello J, Sole-Violan J, Sa-Borges M, et al. Pneumonia caused by oxacillin-resistant Staphylococcus aureus treated with glycopeptides. Crit Care Med 2005; 33: 1983-7.
52. Nathwani D, Tillotson G. Vancomycin for Staphylococcus aureus therapy of respiratory tract infections; the end of an era? Int J Antimicrob Agents 2003; 21: 521-4.
53. Rello J, Mallol J. Optimal therapy for Methicillin-resistant Staphylococcus aureus pneumonia; What is the best dosing regimen? Chest 2006; 130: 938-40.
54. Jeffres M, Isakow W, Doherty J, et al. Predictors of mortality for methicillin-resistant Staphylococcus aureus health-care associated pneumonia. Specific evaluation of vancomycin pharmacokinetic indices. Chest 2006; 130: 947-55.
55. Lodise TP, Lomaestro BM, Graves J, Drusano GL. Larger vancomycin doses (at least Four Grams per Day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother 2008; 52: 1330-6.
56. Jeffres M, Isakow W, Doherty J, Micek ST, Kollef MK. A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care-associated methicillin-resistant Staphylococcus aureus pneumonia. Clin Ther 2007; 29: 1107-15.
57. Kollef MK, Rello J, Cammarata SK, Croos-Dabrera RV, Wunderink RG. Clinical cure and survival in Gram-positive ventillator-associated pneumonia; Retrospective analysis of two double-blind studies comparing linezolid with vancomycin. Intensive Care Med 2004; 30: 388-94.
58. Wunderink RG, Rello J, Cammarata SK, Croos-Dabrera RV, Kollef MK. Linezolid vs Vancomycin. Analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 2003; 124: 1789-96.
59. Conte JE, Golden JA, Kipps J, Zurlinden E. Intrapulmonary pharmacokinetics of linezold. Antimicrob Agents Chemother 2002; 46: 1475-80.
60. Wunderink RG, Mendelson M, Somero M, et al. Early Microbiological response to linezolid vs vancomycin in ventilator-associated pneumonia due to methicillin-resistant Staphylococcus aureus. Chest 2008; 134: 1200-7.
61. Silverman JA, Mortin LI, Vanpraagh AD, Li T, Alder J. Inhibition of daptomycin by pulmonary surfactant; in vitro modeling and clinical impact. J Infect Dis 2005; 191: 2149-52.
62. Fagon J, Patrick H, Haas DW, et al. Treatment of gram-positive nosocomial pneumonia. Prospective randomized comparison of quinupristin/ dalfopristin versus vancomycin. Nosocomial Pneumonia Group. Am J Respir Crit Care Med 2000; 161(3 Pt 1): 753-62.
63. Florescu I, Beuran M, Dimov R, et al. Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci; A phase 3, multicentre, double-blind, randomized study. J Antimicrob Chemother 2008; 62(Suppl 1): i17-i28.
64. Hegde S, Reyes N, Skinner R, Difuntorum S. Efficacy of telavancin in a murine model of pneumonia induced by methicillin-susceptible Staphylococcus aureus. Antimicrob Chemother 2008; 61: 169-72.
65. Lodise TP, Gotfried M, Barriere S, Drusano GL. Telavancin penetration into human epithelial lining fluid determined by population pharmacokinetic modeling and Monte Carlo simulation. Antimicrob Agents Chemother 2008; 52: 2300-4.
66. Anderson S, Gums J. Ceftobiprole; An extended-spectrum antimethicillin-resistant Staphylococcus aureus cephalosporin. Ann Pharmacother 2008; 42: 806-16.